Bharat Parenterals Ltd has received the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of " Favipiravir Oral Suspension l00mg/ml" which will be used for treatment of COVID19 disease.

Further, the product patent has been already filed under fast track approval and the company is the first one in the Indian Market receiving the license and authorization to manufacture and market "Favipiravir Oral Suspension l00mg/ml".